Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
- None.
- None.
Insights
The proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb for $14.0 billion is a significant development with direct implications for shareholders and potential investors. The equity value per share of $330.00 represents a substantial premium, which is a strong indicator of the value Bristol Myers Squibb sees in Karuna's pipeline, particularly KarXT. The transaction's expected closure in the first half of 2024 will be a pivotal moment for both companies.
From a financial perspective, Karuna's increased net loss for the year, primarily due to higher R&D and G&A expenses, reflects their aggressive investment in clinical programs and pre-commercialization efforts. While these expenses are substantial, they are not unexpected in the biopharmaceutical industry, where product development is capital-intensive. The company's completion of a follow-on public offering, resulting in net proceeds of $436.7 million, demonstrates investor confidence and provides a solid cash reserve to fund ongoing operations.
The clinical progress of KarXT, particularly the NDA acceptance for the treatment of schizophrenia, is a strong indicator of Karuna's potential to impact the psychiatric treatment landscape. The statistically significant results from the EMERGENT trials suggest that KarXT could offer a novel therapeutic option for schizophrenia with a favorable safety profile, addressing a significant unmet medical need. This could lead to a substantial market opportunity upon approval, given the chronic nature of schizophrenia and the limitations of current treatments.
The investigation of KarXT as an adjunctive treatment for schizophrenia and for psychosis in Alzheimer's disease further illustrates the breadth of Karuna's pipeline. The potential expansion into these indications could significantly increase the drug's total addressable market, contributing to the long-term commercial viability of the product.
The strategic acquisition of Karuna by Bristol Myers Squibb underscores a trend in the pharmaceutical industry where large companies seek to bolster their pipelines through mergers and acquisitions. The focus on innovative therapies for mental health disorders, a historically underserved area, aligns with growing market demand for new treatments. As the prevalence of psychiatric and neurological conditions rises globally, the market for such therapies is expected to grow, potentially benefiting Bristol Myers Squibb and its stakeholders.
Investors will be closely monitoring the PDUFA date for KarXT and subsequent market launch, as these events will likely influence Karuna's stock performance and validate Bristol Myers Squibb's investment. The anticipation of topline data from additional Phase 3 trials in the coming years will also maintain investor interest, as these results could further define KarXT's therapeutic profile and market potential.
New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults under review with a Prescription Drug User Fee Act (PDUFA) action date of September 26, 2024
Results from the Phase 3 EMERGENT-2 trial of KarXT in schizophrenia published in The Lancet
Announced appointments of Andrew Miller, Ph.D. as President of Research and Development and Mia Kelley, J.D. as General Counsel
Previously announced proposed acquisition of Karuna by Bristol Myers Squibb expected to close in the first half of 2024
“2023 was a landmark year for Karuna, marked by the FDA acceptance of our NDA for KarXT for the treatment of schizophrenia in adults, with a potential launch in the second half of this year, and the continued advancement of our late-stage pipeline of KarXT as a potential adjunctive treatment for schizophrenia and in psychosis in Alzheimer’s disease,” said Bill Meury, president and chief executive officer of Karuna Therapeutics. “We look forward to continuing the work to bring KarXT and other potentially transformative medicines to patients living with serious mental illnesses, and we believe the pending acquisition of Karuna by Bristol Myers Squibb will accelerate our ability to achieve this mission.”
KEY PIPELINE HIGHLIGHTS
Karuna is advancing a pipeline of novel drug candidates for the treatment of various psychiatric and neurological conditions led by KarXT (xanomeline-trospium), an oral, investigational M1/M4-preferring muscarinic agonist.
KarXT
The NDA for KarXT for the treatment of schizophrenia in adults is under review by the
-
Schizophrenia
-
The NDA for KarXT for the treatment of schizophrenia in adults was accepted for review by the FDA in the fourth quarter of 2023 and assigned a PDUFA action date of September 26, 2024.
-
Results from the EMERGENT-2 trial published in The Lancet in December 2023. The published manuscript, titled “Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the
USA : results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial,” is available online, and appears in the January 13, 2024 print issue.
-
Announced positive results from the Phase 1b Ambulatory Blood Pressure Monitoring trial in schizophrenia in the fourth quarter of 2023. Results from the trial demonstrate that KarXT was not associated with clinically meaningful increases in blood pressure in adults with schizophrenia.
-
Presented additional data from the EMERGENT program at the 2023 Neuroscience Education Institute (NEI) Congress and the CNS Summit in the fourth quarter of 2023. Poster presentations included new pooled efficacy and safety analyses across the three completed EMERGENT-1, EMERGENT-2, and EMERGENT-3 trials, where:
- KarXT demonstrated statistically significant and clinically meaningful improvements in symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS) total score from baseline to week 5 compared to placebo (p<0.0001), the primary endpoint in the trials.
- KarXT demonstrated statistically significant improvements across all secondary efficacy measures, including the PANSS positive subscale score (p<0.0001), PANSS negative subscale score (p<0.0001), PANSS Marder negative factor score (p<0.0001), and CGI-S score (p<0.0001).
-
KarXT was generally well tolerated, with common adverse reactions (>
5% and at least twice placebo) being mostly cholinergic in nature, mild to moderate in severity, and transient over time. Further, KarXT was not associated with weight gain, adverse changes in metabolic parameters, or extrapyramidal symptoms.
-
Interim long-term data from the EMERGENT-4 & 5 trials to be presented at upcoming medical congresses in the spring.
-
The NDA for KarXT for the treatment of schizophrenia in adults was accepted for review by the FDA in the fourth quarter of 2023 and assigned a PDUFA action date of September 26, 2024.
-
Adjunctive treatment in schizophrenia
-
Topline data from the Phase 3 ARISE trial evaluating the efficacy and safety of KarXT in schizophrenia when combined with a background antipsychotic is anticipated in 2025.
-
Topline data from the Phase 3 ARISE trial evaluating the efficacy and safety of KarXT in schizophrenia when combined with a background antipsychotic is anticipated in 2025.
-
Psychosis in Alzheimer’s disease
- Topline data from the Phase 3 ADEPT-1 and ADEPT-2 trials evaluating KarXT in psychosis in Alzheimer’s disease is anticipated in 2026.
Early-stage and discovery programs
The Karuna pipeline also includes clinical-stage candidate KAR-2618, a TRPC4/5 inhibitor for the treatment of mood and anxiety disorders, as well as pre-clinical muscarinic, TRPC4/5, and target-agnostic compounds for the treatment of psychiatric and neurological conditions.
- The Company is on track to initiate a Phase 1b trial of KAR-2618 in major depressive disorder (MDD) in 2024.
BUSINESS UPDATES
- Key leadership appointments. In January 2024, the Company appointed Andrew Miller, Ph.D. as President of Research and Development and Mia Kelley, J.D. as General Counsel. Dr. Miller succeeds Steve Paul, M.D., who continues to serve on the Company’s Board of Directors and was appointed as a member of the Company’s Scientific Advisory Board.
-
Proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb. In December 2023, Karuna and Bristol Myers Squibb announced they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for
$330.00 $14.0 billion $12.7 billion
ANTICIPATED UPCOMING MILESTONES
- Topline data from the Phase 3 EMERGENT-4 trial (2H 2024)
- Topline data from the Phase 3 EMERGENT-5 trial (2H 2024)
- KarXT in schizophrenia PDUFA action date (September 26, 2024)
- Launch of KarXT in schizophrenia, if approved (2H 2024)
- Initiation of the Phase 1b trial of KAR-2618 in major depressive disorder (2024)
- Topline data from the Phase 3 ARISE trial (2025)
- Topline data from the Phase 3 ADEPT-1 trial (2026)
- Topline data from the Phase 3 ADEPT-2 trial (2026)
FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
The Company reported a net loss of
Research and development expenses were
General and administrative expenses were
The Company ended the year 2023 with
About Karuna Therapeutics
Karuna Therapeutics is a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by serious mental illness. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples’ lives. For more information, please visit www.karunatx.com.
Forward Looking Statements
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations about the timing of our ongoing and planned clinical trials and regulatory filings, our goals to develop and commercialize our product candidates, our liquidity and capital resources, the proposed acquisition of Karuna by Bristol Myers Squibb, and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to obtain necessary funding, our ability to generate positive clinical trial results for our product candidates and other risks inherent in clinical development, the timing and scope of regulatory approvals, the proposed acquisition of Karuna by Bristol Myers Squibb, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, risks relating to business interruptions, and other risks set forth under the heading “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2023 and in our subsequent filings with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.
Karuna Therapeutics, Inc.
|
||||||||||||||||
|
|
Three Months Ended |
|
|
Year Ended |
|
||||||||||
|
|
December 31, |
|
|
December 31, |
|
||||||||||
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
||||
License and other revenue |
|
$ |
— |
|
|
$ |
5,278 |
|
|
$ |
654 |
|
|
$ |
10,637 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
82,192 |
|
|
|
66,004 |
|
|
|
364,101 |
|
|
|
224,247 |
|
General and administrative |
|
|
47,394 |
|
|
|
24,310 |
|
|
|
131,330 |
|
|
|
76,066 |
|
Total operating expenses |
|
|
129,586 |
|
|
|
90,314 |
|
|
|
495,431 |
|
|
|
300,313 |
|
Loss from operations |
|
|
(129,586 |
) |
|
|
(85,036 |
) |
|
|
(494,777 |
) |
|
|
(289,676 |
) |
Other income, net: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income |
|
|
16,285 |
|
|
|
9,567 |
|
|
|
61,179 |
|
|
|
14,178 |
|
Sublease income |
|
|
147 |
|
|
|
147 |
|
|
|
588 |
|
|
|
580 |
|
Total other income, net |
|
|
16,432 |
|
|
|
9,714 |
|
|
|
61,767 |
|
|
|
14,758 |
|
Net loss before income taxes |
|
|
(113,154 |
) |
|
|
(75,322 |
) |
|
|
(433,010 |
) |
|
|
(274,918 |
) |
Income tax provision |
|
|
(670 |
) |
|
|
(890 |
) |
|
|
(670 |
) |
|
|
(1,418 |
) |
Net loss attributable to common stockholders |
|
$ |
(113,824 |
) |
|
$ |
(76,212 |
) |
|
$ |
(433,680 |
) |
|
$ |
(276,336 |
) |
Net loss per share, basic and diluted |
|
$ |
(3.01 |
) |
|
$ |
(2.22 |
) |
|
$ |
(11.73 |
) |
|
$ |
(8.74 |
) |
Weighted average common shares outstanding used in computing net loss per share, basic and diluted |
|
|
37,780,998 |
|
|
|
34,406,182 |
|
|
|
36,959,049 |
|
|
|
31,629,013 |
|
Karuna Therapeutics, Inc.
|
||||||||
|
|
December 31, 2023 |
|
|
December 31, 2022 |
|
||
Cash, cash equivalents and investments |
|
$ |
1,260,780 |
|
|
$ |
1,124,044 |
|
Working capital |
|
|
1,247,184 |
|
|
|
1,120,823 |
|
Total assets |
|
|
1,336,209 |
|
|
|
1,163,334 |
|
Total stockholders’ equity |
|
$ |
1,254,235 |
|
|
$ |
1,126,238 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222875274/en/
Investors:
Alexis Smith
+1 (617) 352-9917
asmith@karunatx.com
Media:
Julie Ciardiello
+1 (917) 647-0159
julie.ciardiello@karunatx.com
Source: Karuna Therapeutics, Inc.
FAQ
What is the NDA review status for KarXT for the treatment of schizophrenia in adults?
What were the results of the Phase 3 EMERGENT-2 trial of KarXT in schizophrenia?
Who were appointed as President of Research and Development and General Counsel at Karuna Therapeutics?
What is the expected closing date for the proposed acquisition of Karuna by Bristol Myers Squibb?
How much cash, cash equivalents, and available-for-sale investment securities does Karuna have?
What were the financial results for Karuna for the fourth quarter and full year ended December 31, 2023?
